Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, July 8, 2015, 39 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $360.00 to $2,410,815.00.

Highlighted Stocks Traded by Insiders:

State Auto Financial (STFC) - FREE Research Report

State Automobile Mutual Insurance Co, who is 10% Owner at State Auto Financial, bought 3,043 shares at $25.57 on July 8, 2015. Following this transaction, the 10% Owner owned 25.9 million shares meaning that the stake was boosted by 0.01% with the 3,043-share transaction.

The shares most recently traded at $24.89, down $0.68, or 2.74% since the insider transaction. Historical insider transactions for State Auto Financial go as follows:

  • 4-Week # shares bought: 8,745
  • 12-Week # shares bought: 60,907
  • 24-Week # shares bought: 228,145

The average volume for State Auto Financial has been 36,100 shares per day over the past 30 days. State Auto Financial has a market cap of $1.0 billion and is part of the financial sector and insurance industry. Shares are up 13.19% year-to-date as of the close of trading on Wednesday.

State Auto Financial Corporation, through its subsidiaries, engages in writing personal, business, and specialty insurance products. It operates through four segments: Personal insurance, Business insurance, Specialty insurance, and Investment operations. The stock currently has a dividend yield of 1.58%. The company has a P/E ratio of 10.0. Currently, there is 1 analyst who rates State Auto Financial a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STFC - FREE

TheStreet Quant Ratings rates State Auto Financial as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full State Auto Financial Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Heritage Insurance Holdings (HRTG) - FREE Research Report

Vattamattam Joseph, who is Director at Heritage Insurance Holdings, sold 5,000 shares at $25.08 on July 8, 2015. Following this transaction, the Director owned 68,141 shares meaning that the stake was reduced by 6.84% with the 5,000-share transaction.

The shares most recently traded at $25.04, down $0.04, or 0.15% since the insider transaction. Historical insider transactions for Heritage Insurance Holdings go as follows:

  • 4-Week # shares sold: 102,669
  • 12-Week # shares sold: 678,911
  • 24-Week # shares sold: 944,957

The average volume for Heritage Insurance Holdings has been 348,800 shares per day over the past 30 days. Heritage Insurance Holdings has a market cap of $742.5 million and is part of the financial sector and insurance industry. Shares are up 27.64% year-to-date as of the close of trading on Wednesday.

Heritage Insurance Holdings, Inc. operates as a property and casualty insurance holding company in the state of Florida. The company has a P/E ratio of 10.4. Currently, there are 2 analysts who rate Heritage Insurance Holdings a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HRTG - FREE

TheStreet Quant Ratings rates Heritage Insurance Holdings as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Heritage Insurance Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Keryx Biopharmaceuticals (KERX) - FREE Research Report

Oliviero James F III, who is Chief Financial Officer at Keryx Biopharmaceuticals, sold 1,943 shares at $9.61 on July 8, 2015. Following this transaction, the Chief Financial Officer owned 209,406 shares meaning that the stake was reduced by 0.92% with the 1,943-share transaction.

The shares most recently traded at $9.67, up $0.06, or 0.62% since the insider transaction. Historical insider transactions for Keryx Biopharmaceuticals go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 4,320
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 4,320
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 14,549

The average volume for Keryx Biopharmaceuticals has been 1.7 million shares per day over the past 30 days. Keryx Biopharmaceuticals has a market cap of $1.0 billion and is part of the health care sector and drugs industry. Shares are down 32.37% year-to-date as of the close of trading on Wednesday.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Currently, there are 8 analysts who rate Keryx Biopharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KERX - FREE

TheStreet Quant Ratings rates Keryx Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Keryx Biopharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.